Author: sugaradmin

Introduction and Objective: Obesity is a chronic disease requiring lifelong management, yet peptide agonists face high discontinuation and rebound weight gain due to dosing burdens. Improving therapeutic persistence requires long-acting agents optimized for weight maintenance. Leveraging antibody-based half-life extension, we developed a potent GIPR antagonist. This study evaluates its cellular potency and metabolic durability in […]

Introduction and Objective: T1D & T2D Dysglycemia impairs intrinsic Mesenchymal Stromal Cells’ (MSCs) protective & regenerative functions including those of pancreatic Islet-intrinsic MSCs. This accelerates b-Cell loss. Replacing MSCs at high numbers within Neo-Islets (NIs) corrects the dysfunction. The MSC component in NIs exerts trophic, anti-inflammatory, auto- and allo-immune modulatory actions (survival, angiogenic, anti-fibrotic). We […]

Introduction and Objective: Real-world studies estimating the impact of substantial weight loss (WL) on vascular events in T2D are scarce. This retrospective cohort study investigated micro- and macrovascular risk after ≥15% WL in adults with newly diagnosed T2D.Methods: Adults with T2D and obesity were identified in UK primary care data from Clinical Practice Research Datalink […]

Introduction and Objective: Diabetes mellitus (DM) is a major risk factor for cognitive decline and dementia, whereas physical activity (PA) may mitigate this risk. However, the combined effects of PA and DM on cognitive function and brain structure remain unclear. We examined whether PA modifies associations of DM with mild cognitive impairment (MCI) and hippocampal […]

Introduction and Objective: There are limited data evaluating both A1C and CGM metrics on a population level. This study assessed Dexcom CGM use on these measures in adults with T2D on non-insulin (NIT), non-intensive insulin (NIIT) and intensive insulin (IIT) therapies.Methods: Truveta EHR data linked at the individual level to Dexcom CGM data were analyzed […]

Introduction and Objective: Obesity is a major driver of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH), conditions with substantial unmet medical need. This study aimed to characterize XWDAPC-1, a novel long-acting β-klotho antibody-GLP-1/GCG/GIP quadragonist, for its metabolic efficacy and pharmacological profile.Methods: The in vitro activity of XWDAPC-1 was evaluated using cell-based […]

Introduction and Objective: An unhealthy diet is associated with obesity, cardiovascular disease and death. Zenagamtide (previously amycretin) is a novel unimolecular GLP1-, amylin- and calcitonin receptor agonist that decreased body weight by up to 24.3% in patients with obesity. As it is unknown if zenagamtide also promotes healthier food choices, we investigated zenagamtide’s distribution to […]

Introduction and Objective: Type 2 diabetes (T2DM) places older adults at risk of unhealthy aging and cognitive decline. Diabetes self-management education and support (DSME/S) is effective but underutilized. We conducted a two-arm randomized trial (DSME/S delivery via an immersive, 3D virtual environment (HOPE) versus a waitlist control group) to assess 6-month changes in glucose control […]

Introduction and Objective: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a major global health challenge with limited effective pharmacological therapies. Although lysine lactylation has emerged as an important regulator of metabolic homeostasis, whether lactylation of the key glycolytic enzyme phosphofructokinase liver type (PFKL) drives MASLD progression and the underlying mechanisms remain obscure.Methods: Quantitative lactylome and […]